TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14577344
Drug: Non-DOT (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-DOT (self-administered therapy) during admission
Study: 8878167
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (50 mg/mL, 216 mL/h)
Study: 8878167
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (9 mg/mL, 3 mL · kg‐1 · h‐1)
Study: 1613673
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (intravenous methylprednisolone 2 mg/kg body weight daily for 10 days)
Study: 1613673
Drug: Control (cotrimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (cotrimoxazole as standard treatment)
Study: 6439835
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (MFC + F): Induction therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside followed by intermittent oral administration of 5-fluorouracil for two years.
Study: 6439835
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (MF'C + F'): Ftorafur administered on the same schedule as regimen A.
Study: 26169691
Drug: 1064-nm Q-switched
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064-nm Q-switched Nd:YAG laser treatment
Study: 18468322
Drug: Prosthodontic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthodontic treatments (specific interventions not detailed)
Study: 18468322
Drug: Denture hygiene
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture hygiene and implants (commercially attractive topics)
Study: 16631060
Drug: Perioperative sub‐Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative sub‐Tenon's injection of triamcinolone (30 mg)
Study: 16631060
Drug: Perioperative sub‐Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative sub‐Tenon's injection of triamcinolone (20 mg)
Study: 16631060
Drug: Steroid drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid drops (control group)
Study: 11704023
Drug: 0.5% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% aqueous timolol (timolol solution)
Study: 11704023
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol suspension (timolol gellan)
Study: 9065721
Drug: Rx 2
Normalized name: SP RX 228
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rx 2 (high-dose carboplatin (HD-CBDCA) 500 mg/m2/day for 2 days and VP-16 100 mg/m2/day for 3 days)
Study: 9065721
Drug: Rx 3
Normalized name: AlleRx 30 Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rx 3 (ifosfamide 1.5 g/m2/day for 3 days followed by carboplatin (CBDCA) 400 mg/m2 on day 4)
Study: 9065721
Drug: Rx 1
Normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rx 1 (high-dose cisplatin (HDP) 200 mg/m2 with concurrent sodium thiosulfate (STS) 9.9 g/m2 and etoposide (VP-16) 200 mg/m2/day for 3 days)
Study: 3318260
Drug: im injection
Normalized name: filgrastim Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: im injection of hGH
Study: 3318260
Drug: sc injection
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc injection of hGH
Study: 23972320
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg
Study: 28947165
Drug: ADL retraining
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ADL retraining during PTA (treatment group)
Study: 28947165
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) alone (control group)
Study: 23093054
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1500 IU) plus fluoxetine (20 mg)
Study: 23093054
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (20 mg)
Study: 18181241
Drug: D-chlorpheniramine 6
Normalized name: chlorpheniramine maleate 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chlorpheniramine 6 mg
Study: 12749509
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg QD given i.v. and then orally for 7 to 15 days
Study: 12749509
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg to 1 g i.v. every 6 to 8 hours, followed by oral ciprofloxacin 750 mg every 12 hours for 7 to 15 days
Study: 26701971
Drug: Single-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose methotrexate (n = 46)
Study: 26701971
Drug: Two-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose methotrexate (n = 46)
Study: 14563972
Drug: UK-279,276 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-279,276 (dose range, 10 to 120 mg)
Study: 15220251
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg/day)
Study: 8546341
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg/day) plus Quinapril (10 mg/day)
Study: 2035513
Drug: Progression from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression from normal glucose tolerance to non-insulin-dependent diabetes
Study: 2035513
Drug: Progression from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression from impaired glucose tolerance to non-insulin-dependent diabetes
Study: 2035513
Drug: Overall age-standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall age-standardized incidence of non-insulin-dependent diabetes
Study: 3909759
Drug: Nifedipine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine slow-release tablets, 20 mg twice daily
Study: 29385062
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1000 mg capsules containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid, n = 20)
Study: 26541738
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.3 mcg/kg/h for 24 hours)
Study: 26541738
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion (3 mg/h for 24 hours)
Study: 24797222
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions
Study: 23198510
Drug: Chlorhexidine gluconate-impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine gluconate-impregnated wipes used thrice weekly
Study: 12669740
Drug: Alendronate therapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate therapy
Study: 18577886
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mosapride citrate
Study: 18577886
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg itopride hydrochloride
Study: 18577886
Drug: Vehicle (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (100 ml water) alone
Study: 12492904
Drug: Control dentifrice
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dentifrice (without anti‐plaque agents)
Study: 10048684
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplements (400,000 IU); given at baseline, 4 months, and 8 months after discharge.
Study: 8579884
Drug: Webril patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Webril patch
Study: 8579884
Drug: Hill Top
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hill Top patch
Study: 2405789
Drug: Dipyridamole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (5 mg/kg/day) for 12 months
Study: 6767959
Drug: Gentamicin once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin once daily (120 mg)
Study: 6767959
Drug: Gentamicin twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin twice daily (40/80 mg)
Study: 6767959
Drug: Gentamicin three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin three times daily (40 mg)
Study: 26831124
Drug: enalapril-lercanidipine (EL)
Normalized name: enalapril and lercanidipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril-lercanidipine (EL) uptitrated to 20 mg/d
Study: 26831124
Drug: enalapril-felodipine (EF)
Normalized name: enalapril / felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril-felodipine (EF) uptitrated to 10 mg/d
Study: 24559212
Drug: Complex small
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex small group educational seminar on antibiotic prescribing
Study: 22251408
Drug: Paricalcitol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (mean initiation dose: 23 ± 7 μg/week)
Study: 21570554
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives (OC)
Study: 17236845
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) mechanical bowel preparation
Study: 17236845
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (SP) mechanical bowel preparation
Study: 17236845
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (SP) with ertapenem antibiotic prophylaxis
Study: 17236845
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) with cefotetan antibiotic prophylaxis
Study: 15059701
Drug: Valganciclovir therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir therapy (900 mg daily)
Study: 15059701
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of valganciclovir therapy
Study: 15059701
Drug: Valganciclovir therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir therapy
Study: 10689236
Drug: Oral ETEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ETEC B-subunit-inactivated whole cell vaccine
Study: 9342768
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg hypericum extract (LI 160)
Study: 9342768
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg hypericum extract (LI 160)
Study: 9342768
Drug: 3600 mg
Normalized name: Ascorbic Acid/Calcium 3600 MG-400 MG Oral Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3600 mg hypericum extract (LI 160)
Study: 9342768
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg hypericum extract t.i.d. (5.6 mg total hypericin daily)
Study: 28230596
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with lyophilized bovine bone granules and pericardium membrane covering
Study: 28230596
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (immediate implants)
Study: 21845472
Drug: Naftopidil 10
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 10 mg once daily
Study: 18482350
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren 3 x 50 mg)
Study: 18482350
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Diclofenac and Occlusal splint therapy)
Study: 10834776
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of isobaric bupivacaine with 25 microg fentanyl
Study: 10834776
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isobaric (plain) bupivacaine 0.5%
Study: 9489085
Drug: Doxazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (0.5 or 1 mg once daily, up to 12 mg once daily)
Study: 8161441
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (exact dosage and duration not specified)
Study: 3526984
Drug: Esmolol (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (infusion rates between 100 and 300 micrograms X kg‐1 X min‐1)
Study: 30070386
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (average duration: 9 weeks)
Study: 24121610
Drug: Subgluteal space
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subgluteal space technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Study: 24121610
Drug: Infragluteal technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infragluteal technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Study: 17951021
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment (SC) as an adjunct to substance abuse treatment-as-usual (TAU)
Study: 17951021
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment (SC)
Study: 17951021
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment-as-usual (TAU)
Study: 14983955
Drug: Serum prostate-specific
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum prostate-specific antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasonography (TRUS) as screening tests
Study: 14983955
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA level > or = 3.0 ng/mL as an indication for sextant biopsy
Study: 7986334
Drug: Live VZV
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live VZV vaccine (4,000 PFU of Oka strain)
Study: 7986334
Drug: Inactivated VZV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated VZV vaccine (similar amount to live vaccine)
Study: 7986334
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) immunization (3 months before VZV vaccine)
Study: 3151688
Drug: Clindamycin 3x80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 3x80 mg and Gentamycin 3x80 mg
Study: 3151688
Drug: Metronidazol 3x500
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazol 3x500 mg and Gentamycin 3x80 mg
Study: 25211695
Drug: Order of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Order of administration with memory descriptions before well-being scales
Study: 25211695
Drug: Order of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Order of administration with well-being scales before memory descriptions
Study: 23594227
Drug: MK-0916 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0916 (6 mg once daily for 14 days)
Study: 23594227
Drug: MK-0916 (0.4-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0916 (0.4-100 mg single doses)
Study: 23594227
Drug: MK-0916 (0.2-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0916 (0.2-225 mg followed by daily doses of 0.2-100 mg for 13 days)
Study: 15131466
Drug: Licensed meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed meningococcal polysaccharide vaccine (A, C, Y, W-135) at 15 to 18 months
Study: 11237270
Drug: Etidronate (2-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (2-week administration)
Study: 2277738
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (0.5 mg b.i.d.)
Study: 23432146
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 or 40 mg once daily for 4 weeks
Study: 23432146
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy (control)
Study: 21310833
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g Acetyl-L-carnitine (ALC) twice a day for 90 days
Study: 21310833
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 90 days
Study: 10471608
Drug: p55‐IgG, 0.083
Approvals — FDA: no, EMA: no, PMDA: no
Description: p55‐IgG, 0.083 mg/kg
Study: 9153367
Drug: p55‐IgG, 0.042
Approvals — FDA: no, EMA: no, PMDA: no
Description: p55‐IgG, 0.042 mg/kg
Study: 9153367
Drug: p55‐IgG (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: p55‐IgG (both doses)
Study: 8162628
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg isosorbide dinitrate (ISDN) treatment for 4 weeks
Study: 8162628
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glyceryl trinitrate (GTN) before ISDN treatment
Study: 8162628
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glyceryl trinitrate (GTN) after ISDN treatment
Study: 31853557
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg LSD
Study: 31853557
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg LSD
Study: 31853557
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg LSD
Study: 28746179
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of NBP soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Study: 28746179
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of placebo soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Study: 23039152
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual therapy)
Study: 18090507
Drug: Escitalopram (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10‐20 mg/day)
Study: 1597847
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg three times daily for four weeks
Study: 30414369
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (calcium channel blockers plus oxygen‐ozone treatment)
Study: 30414369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium channel blockers only)
Study: 24556445
Drug: ECV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECV with antiarrhythmic drugs (mostly amiodarone)
Study: 24556445
Drug: PCV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV with class Ic antiarrhythmic drugs
Study: 24556445
Drug: Chronic antiarrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiarrhythmic drugs, beta-blockers, or inhibitors of the renin-angiotensin system
Study: 22098133
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus L. gasseri-containing yogurt (112 g, twice daily for 4 weeks)
Study: 22098133
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Study: 22098133
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus L. gasseri-containing yogurt
Study: 1100308
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin
Study: 14985668
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin
Study: 14985668
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin vs Intravenous phenytoin
Study: 14985668
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin vs Intravenous phenytoin
Study: 8052154
Drug: D-fenfluramine 15
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fenfluramine 15 mg twice daily
Study: 26634956
Drug: Buprenorphine (BBUP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (BBUP) 150-450 µg every 12 hours
Study: 21931012
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser treatment (EVLT)
Study: 20873270
Drug: Nutrition optimization
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition optimization as part of maintenance therapy
Study: 9347122
Drug: d-amphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.25 mg/kg)
Study: 16815467
Drug: levodopa/carbidopa (100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/carbidopa (100/25 mg)
Study: 1448534
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheets (Spenco) worn continuously for 12 hours for 12 weeks
Study: 1448534
Drug: Kenalog injection
Normalized name: triamcinolone Injection [Kenalog]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kenalog injection (40 mg/ml x 1 cc mixed with 1 cc of 1% Xylocaine with epinephrine)